Ina-Respond Report issue

Academic/Hospital Phase 1 Phase 3

Organization Overview

First Clinical Trial
2020
NCT04613271
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Ina-Respond